Heck Capital Advisors LLC acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 14,810 shares of the company's stock, valued at approximately $316,000.
Other institutional investors have also modified their holdings of the company. B. Riley Wealth Advisors Inc. raised its stake in Kenvue by 18.1% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 32,455 shares of the company's stock valued at $693,000 after purchasing an additional 4,974 shares during the period. Pullen Investment Management LLC grew its holdings in shares of Kenvue by 46.7% during the fourth quarter. Pullen Investment Management LLC now owns 69,907 shares of the company's stock valued at $1,493,000 after buying an additional 22,250 shares in the last quarter. Mackenzie Financial Corp raised its position in Kenvue by 12.8% during the fourth quarter. Mackenzie Financial Corp now owns 444,128 shares of the company's stock valued at $9,482,000 after buying an additional 50,279 shares during the period. Forum Financial Management LP grew its stake in Kenvue by 29.2% during the 4th quarter. Forum Financial Management LP now owns 22,917 shares of the company's stock valued at $489,000 after acquiring an additional 5,174 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Kenvue in the 4th quarter valued at about $8,229,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Performance
KVUE traded down $0.00 during trading on Thursday, reaching $23.55. 19,711,476 shares of the company's stock were exchanged, compared to its average volume of 16,343,223. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $23.25 and a 200 day moving average price of $22.64. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The company has a market capitalization of $45.18 billion, a P/E ratio of 44.43, a PEG ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company's quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 earnings per share. As a group, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.48%. Kenvue's dividend payout ratio is 149.09%.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on KVUE. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Barclays upped their target price on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Kenvue presently has an average rating of "Hold" and an average target price of $25.33.
View Our Latest Stock Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
